Hepatitis C
FDA Lifts Hold on Idenix HCV Polymerase Inhibitor IDX184
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 07 February 2012 00:00
The U.S. Food and Drug Administration (FDA) last week gave the go-ahead for further development of Idenix Pharmaceuticals' hepatitis C virus (HCV) nucleotide polymerase inhibitor IDX184. The agency lifted a hold imposed after a few healthy volunteers who received a combination of IDX184 plus another experimental agent, IDX321, in an early clinical trial developed elevated liver enzymes; further analysis indicates that liver toxicity is likely attributable to the second drug.
Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels
- Details
- Category: Acute Hepatitis C
- Published on Tuesday, 07 February 2012 00:00
HIV/HCV coinfected people who take the HCV protease inhibitor boceprevir (Victrelis) for hepatitis C treatment along with a ritonavir-boosted HIV protease inhibitor may experience drug-drug interactions that reduce concentrations of both drugs to ineffective levels, Merck warned this week.
Achillion, Presidio, Idenix Announce HCV Drug Pipeline Developments
- Details
- Category: HCV Treatment
- Published on Tuesday, 17 January 2012 00:00
Three companies developing direct-acting antiviral agents (
DAAs) for hepatitis C virus (HCV) infection recently announced progress on new experimental drug candidates.
European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People
- Details
- Category: Acute Hepatitis C
- Published on Tuesday, 31 January 2012 00:00
People who are already HIV positive when they acquire hepatitis C virus (HCV) may not experience unusually rapid liver disease progression over the long term, even though the fibrosis progression rate may appear high during the acute stage of infection, according to a European FibroScan study described in the February 15, 2012, issue of Clinical Infectious Diseases.
Experimental Hepatitis C Vaccine Triggers T-Cell Responses in Early Clinical Trial
- Details
- Category: HCV Vaccines
- Published on Tuesday, 10 January 2012 00:00
An investigational adenovirus-based hepatitis C virus (HCV) vaccine induced sustained T-cell responses and cytokine production in a small Phase 1 study of healthy volunteers, according to findings reported in the January 4, 2012, issue of Science Translational Medicine.
Researchers Show How Cholesterol Receptor Promotes HCV Cell Entry
- Details
- Category: HCV Basic Science
- Published on Friday, 27 January 2012 00:00
A molecule in liver cell membranes that plays a role in cholesterol uptake also enables hepatitis C virus (HCV) to enter cells, according to research reported in the January 8, 2012, advance online edition of Nature Medicine.
Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
Pharmasset announced in December that it would change the design of its ongoing QUANTUM trial to discontinue treatment with its hepatitis C virus (HCV) nucleotide polymerase inhibitor PSI-938, after routine safety monitoring revealed liver function abnormalities.
High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 24 January 2012 00:00
A dual oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (BMS-790052) cleared the virus in one-third of genotype 1 prior null responders to prior interferon-based therapy, and both of those with genotype 1b, according to data published in the January 19, 2012, New England Journal of Medicine.
AASLD 2011: Sustained Response is Durable among Hepatitis C Patients Treated with Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
Almost all chronic hepatitis C patients who achieved sustained virological response (SVR) using the recently approved HCV protease inhibitor telaprevir (Incivek) plus pegylated interferon and ribavirin continued to have undetectable viral load nearly 2 years later, according to data presented at the recent American Association for the Study of Liver Disease (AASLD) Liver Meeting in San Francisco.
More Articles...
- Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
- PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- AASLD 2011: Fever Signals Responsiveness to Pegylated Interferon for Hepatitis C
- AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Novel P7 Inhibitor BIT225 Improves Hepatitis C Response, also Inhibits HIV
Web Design and Development by